NALA-Drug Comparator study in HER2+ Metastatic Breast Cancer patients

• Research type

  Research Study

• Full title

  A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

• IRAS ID

  111478

• Contact name

  Stephen Chan

• Contact email

  Steve.Chan@nuh.nhs.uk

• Sponsor organisation

  Puma Biotechnology, Inc.

• Eudract number

  2012-004492-38

• Clinicaltrials.gov Identifier

  NCT01808573

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  13/EM/0189

• Date of REC Opinion

  30 Jul 2013

• REC opinion

  Further Information Favourable Opinion